Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4259 | 1742 | 33.4 | 69% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
81 | 26583 | MYELODYSPLASTIC SYNDROMES//ACUTE MYELOID LEUKEMIA//LEUKEMIA |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | SECONDARY LEUKEMIA | Author keyword | 38 | 46% | 4% | 61 |
2 | SECOND MALIGNANT NEOPLASM | Author keyword | 20 | 51% | 2% | 28 |
3 | THERAPY RELATED | Author keyword | 15 | 46% | 1% | 24 |
4 | THERAPY RELATED LEUKEMIA | Author keyword | 15 | 42% | 2% | 27 |
5 | SECOND MALIGNANCY | Author keyword | 15 | 28% | 3% | 44 |
6 | THERAPY RELATED MYELODYSPLASTIC SYNDROME | Author keyword | 13 | 55% | 1% | 16 |
7 | THERAPY RELATED ACUTE MYELOID LEUKEMIA | Author keyword | 9 | 55% | 1% | 11 |
8 | THERAPY RELATED MYELOID NEOPLASMS | Author keyword | 9 | 55% | 1% | 11 |
9 | THERAPY RELATED MYELODYSPLASIA | Author keyword | 8 | 70% | 0% | 7 |
10 | THERAPY RELATED AML | Author keyword | 6 | 44% | 1% | 11 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | 2ND MALIGNANT NEOPLASMS | 48 | 31% | 7% | 130 |
2 | SECONDARY LEUKEMIA | 35 | 43% | 4% | 62 |
3 | FAVORABLE CYTOGENETIC ABNORMALITIES | 29 | 75% | 1% | 21 |
4 | THERAPY RELATED LEUKEMIA | 26 | 38% | 3% | 55 |
5 | 2ND MALIGNANCY | 26 | 42% | 3% | 47 |
6 | ACUTE MYELOPROLIFERATIVE SYNDROME | 24 | 82% | 1% | 14 |
7 | 1ST CANCER | 17 | 75% | 1% | 12 |
8 | 5 YEAR SURVIVORS | 9 | 15% | 3% | 56 |
9 | CHEMOTHERAPY INDUCED LEUKEMIA | 9 | 83% | 0% | 5 |
10 | 2ND CANCERS | 9 | 15% | 3% | 53 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Therapy-related myeloid leukemia | 2008 | 73 | 41 | 54% |
Secondary cancers: Incidence, risk factors and recommendations | 2015 | 1 | 34 | 56% |
Therapy-related myelodysplastic syndrome | 2015 | 1 | 75 | 44% |
Second Solid Cancers After Radiation Therapy: A Systematic Review of the Epidemiologic Studies of the Radiation Dose-Response Relationship | 2013 | 16 | 46 | 37% |
A focused review of hematopoietic neoplasms occurring in the therapy-related setting | 2014 | 5 | 65 | 48% |
Systematic Review: Surveillance for Breast Cancer in Women Treated With Chest Radiation for Childhood, Adolescent, or Young Adult Cancer | 2010 | 39 | 67 | 43% |
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation | 2000 | 117 | 53 | 70% |
Genetic Variation as a Modifier of Association Between Therapeutic Exposure and Subsequent Malignant Neoplasms in Cancer Survivors | 2015 | 1 | 87 | 30% |
Acute Leukemia as a Secondary Malignancy in Children and Adolescents Current Findings and Issues | 2009 | 36 | 88 | 52% |
Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia | 2013 | 7 | 25 | 52% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RUBIN CANC SURVIVORSHIP | 6 | 53% | 0.5% | 8 |
2 | CHILDHOOD CANC SURVIVOR STUDIES | 6 | 32% | 0.9% | 15 |
3 | SECT 4052 | 4 | 75% | 0.2% | 3 |
4 | U605 | 2 | 20% | 0.4% | 7 |
5 | BRITISH LYMPHOMA INVEST | 1 | 30% | 0.2% | 3 |
6 | NEUROONCOEMATOL | 1 | 17% | 0.2% | 4 |
7 | ADULT ONCOL UNIT | 1 | 50% | 0.1% | 1 |
8 | CANC N CAROLINA | 1 | 50% | 0.1% | 1 |
9 | CANC PREVENT CLIN STAT PROGRAMS | 1 | 50% | 0.1% | 1 |
10 | CLIN DEV HEMATOL ONCOL | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000192196 | CHROMOSOME 5 ABNORMALITY//PHARM NTHC NARILIS//UNIDAD HEMATOL CLIN |
2 | 0.0000157654 | HODGKINS DISEASE//HODGKIN LYMPHOMA//HODGKINS LYMPHOMA |
3 | 0.0000141618 | MULTIPLE PRIMARY MALIGNANCIES//MULTIPLE PRIMARY MALIGNANT NEOPLASMS//MULTIPLE PRIMARY NEOPLASMS |
4 | 0.0000138701 | RADIATION INDUCED MENINGIOMA//RADIATION INDUCED TUMOR//RADIATION INDUCED GLIOMA |
5 | 0.0000119461 | GENITAL GVHD//CARDIAC LATE EFFECTS//HCT HEMATOPOIETIC CELL TRANSPLANTATION |
6 | 0.0000104124 | CHRONIC NEUTROPHILIC LEUKEMIA//CHRONIC NEUTROPHILIC LEUKAEMIA//COLONY STIMULATING FACTOR 3 RECEPTOR MUTATION |
7 | 0.0000090534 | MLL//MLL GENE//11Q23 |
8 | 0.0000082789 | NUCLEAR WORKERS//ATOMIC BOMB SURVIVORS//RADIAT EPIDEMIOL BRANCH |
9 | 0.0000074082 | TETRASOMY 8//NEAR TETRAPLOIDY//TRISOMY 4 |
10 | 0.0000063086 | PERIPHERAL DOSE//PHOTONEUTRONS//ACCELERATORS MEDICAL |